Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Chief Innovation/Tech Officer | March 09, 2024 | October 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date March 09, 2024 · Filed October 02, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 980,726 |
Reported balance
After 2024-03-09 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-03-09 · Tax withholding · Disposed 9,645 · Balance 980,726 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. This amended Form 4 is being filed to revise the number of shares withheld by the issuer to satisfy tax withholding obligations originally reported on form 4 filed on March 12, 2024 . |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. This amended Form 4 is being filed to revise the number of shares withheld by the issuer to satisfy tax withholding obligations originally reported on form 4 filed on March 12, 2024 .
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2019 Filed Jul 2, 2019 16:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-004458 · marketforms-45276.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-003980 · marketforms-45121.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,288 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,591 | $3.72 | $24,518.52 |
DisclosureSEC source: 0001214659-19-003980 · marketforms-45121.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,689 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:15 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-003980 · marketforms-45121.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,042,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 31, 2019 Filed Apr 1, 2019 16:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-002419 · marketforms-44721.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,649 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| March 31, 2019 Filed Apr 1, 2019 16:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 263 | $6.91 | $1,817.33 |
DisclosureSEC source: 0001214659-19-002419 · marketforms-44721.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,708 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 31, 2019 Filed Apr 1, 2019 16:40 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-002419 · marketforms-44721.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:23 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Units · Derivative | 14,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-001723 · marketforms-44305.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,860 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:23 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,721 | $8.05 | $54,104.05 |
DisclosureSEC source: 0001214659-19-001723 · marketforms-44305.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,642 F2 · kind: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:23 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-19-001723 · marketforms-44305.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:50 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001214659-19-001754 · marketforms-44356.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · SVP,Chief Innov/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 17:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Unit · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-19-000283 · form4.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,978 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F2 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 17:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 162 | $6.30 | $1,020.60 |
DisclosureSEC source: 0001140361-19-000283 · form4.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,791 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 17:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-19-000283 · form4.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 10, 2018 Filed Dec 11, 2018 17:41 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,000 | $7.78 | $7,780.00 |
DisclosureSEC source: 0001140361-18-044950 · form4.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,624 Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 17:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 2,000 | $8.69 | $17,380.00 |
DisclosureSEC source: 0001140361-18-044870 · form4.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,624 Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Unit · Derivative | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-044536 · form4.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,432 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F2 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 7,177 | $8.59 | $61,650.43 |
DisclosureSEC source: 0001140361-18-044536 · form4.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,016,624 Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 16:05 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-044536 · form4.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 13:43 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,000 | $10.25 | $10,250.00 |
DisclosureSEC source: 0001140361-18-043656 · form4.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,229 Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 16:37 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Unit · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-039942 · form4.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,307 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F2 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 16:37 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 162 | $17.51 | $2,836.62 |
DisclosureSEC source: 0001140361-18-039942 · form4.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,229 Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 16:37 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-039942 · form4.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 17:39 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionRestricted Stock Unit · Derivative | 14,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-037868 · form4.xml · derivative · entry 3 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,004 Underlying: Common Stock · 14,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F2 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 17:39 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,510 | $18.01 | $117,245.10 |
DisclosureSEC source: 0001140361-18-037868 · form4.xml · nonDerivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,062 Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 17:39 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 14,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-037868 · form4.xml · nonDerivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 18:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantRestricted Stock Unit · Derivative | 2,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-036639 · form4.xml · derivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,636 Underlying: Common Stock · 2,636 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F3 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 18:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 28,043 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001140361-18-036639 · form4.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,043 Underlying: Common Stock · 28,043 shares Expires 2028-08-15 F1 · derivative.exercise_date: The shares underlying the options vest in 36 equal (or as nearly equal as possible) monthly installments beginning on September 30, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantRestricted Stock Unit · Derivative | 116,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033737 · form4.xml · derivative · entry 2 Schobel Alexander Mark · CIK 0001406836 · Director · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,576 Underlying: Common Stock · 116,576 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. F3 · derivative.expiration_date: The restricted stock units vest in 8 equal (or as nearly equal as possible) quarterly installments beginning on August 31, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date thereof. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 240,165 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033737 · form4.xml · derivative · entry 1 Schobel Alexander Mark · CIK 0001406836 · Director · Chief Innovation/Tech Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,165 Underlying: Common Stock · 240,165 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares underlying the options vest in 36 equal (or as nearly equal as possible) monthly installments beginning on August 31, 2018, subject in each case to Mr. Schobel's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.